Damora Therapeutics Reports 2025 Results and Pipeline Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy DMRA?
Source: NASDAQ.COM
- Financial Overview: Damora Therapeutics ended 2025 with $257.6 million in cash, which increased to $535 million following a public offering in February 2026, providing essential funding for Phase 3 development, despite reporting a net loss of $209.8 million, significantly higher than the previous year's $21.4 million, primarily due to costs associated with the acquisition of the mutCALR pipeline.
- Pipeline Progress: The company's lead program, DMR-001, is on track for an IND/CTA filing in mid-2026, with two proof-of-concept readouts expected in 2027, indicating its potential in treating mutant calreticulin-driven blood disorders.
- New Therapy Development: DMR-002 and DMR-003 are respectively an undisclosed mutCALR-targeted therapy and a bispecific antibody, with IND/CTA submissions anticipated in the second half of 2026 and 2027, further enhancing Damora's competitive position in the market.
- Stock Split Impact: The company implemented a 1-for-25 reverse stock split on August 26, 2024; despite a 9.22% drop in stock price to $19.20 on Thursday, it slightly rebounded to $19.21 in pre-market trading, reflecting cautious optimism in the market regarding its future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DMRA
Wall Street analysts forecast DMRA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.920
Low
Averages
High
Current: 23.920
Low
Averages
High
About DMRA
Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Damora Therapeutics Appoints New CEO and Board Members
- New CEO Appointment: Damora Therapeutics has appointed Jennifer Jarrett as the new CEO, effective March 30, 2026, aiming to leverage her extensive experience in the biopharmaceutical sector to drive strategic growth for the company.
- Board Expansion: Jarrett will also serve on the Board of Directors, enhancing the company's governance structure and decision-making efficiency, which is expected to positively impact the company's long-term growth trajectory.
- New Board Members: The company has appointed Cameron Turtle and Mike Landsittel to the Board, with Turtle being the CEO of Spyre Therapeutics and Landsittel a former CFO of Blueprint Medicines, bringing additional industry expertise and resources to the company.
- Chairman Change: Peter Harwin has been named Chairman of the Board, and as a founding partner at Fairmount Funds Management, his leadership is expected to enhance the company's influence in capital markets, supporting future financing and strategic planning.
See More
Damora Therapeutics Names Biotechnology Expert Jennifer Jarrett as President and CEO; Welcomes Two Industry Veterans to Board of Directors
New Leadership Appointment: Damo Therapeutics has appointed Jennifer Jarrett as President and Chief Executive Officer, enhancing its leadership team.
Board Expansion: The company has also added two industry veterans to its Board of Directors, aiming to strengthen its strategic direction.
See More
Damora Therapeutics Reports 2025 Results and Pipeline Progress
- Financial Overview: Damora Therapeutics ended 2025 with $257.6 million in cash, which increased to $535 million following a public offering in February 2026, providing essential funding for Phase 3 development, despite reporting a net loss of $209.8 million, significantly higher than the previous year's $21.4 million, primarily due to costs associated with the acquisition of the mutCALR pipeline.
- Pipeline Progress: The company's lead program, DMR-001, is on track for an IND/CTA filing in mid-2026, with two proof-of-concept readouts expected in 2027, indicating its potential in treating mutant calreticulin-driven blood disorders.
- New Therapy Development: DMR-002 and DMR-003 are respectively an undisclosed mutCALR-targeted therapy and a bispecific antibody, with IND/CTA submissions anticipated in the second half of 2026 and 2027, further enhancing Damora's competitive position in the market.
- Stock Split Impact: The company implemented a 1-for-25 reverse stock split on August 26, 2024; despite a 9.22% drop in stock price to $19.20 on Thursday, it slightly rebounded to $19.21 in pre-market trading, reflecting cautious optimism in the market regarding its future developments.
See More
Galecto Reports Disappointing FY Earnings with Significant EPS Miss
- Disappointing Earnings Report: Galecto's FY earnings report reveals a GAAP EPS of -$3.98, missing expectations by $3.02, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, Galecto reported cash and cash equivalents of approximately $257.6 million, which, while providing some liquidity, may be insufficient to support ongoing operations amid persistent losses.
- Executive Appointments: The company has appointed former Blueprint Medicines executives as COO and CMO, aiming to enhance strategic direction and operational efficiency through experienced leadership, potentially improving competitive positioning in the market.
- Market Sentiment Outlook: Given the disappointing earnings and executive changes, market sentiment towards Galecto is expected to be cautious, which may lead to stock price volatility and affect long-term investor confidence.
See More
Damora Therapeutics Appoints New CEO and Board Members
- New CEO Appointment: Damora Therapeutics has appointed Jennifer Jarrett as the new CEO, effective March 30, 2026, aiming to leverage her extensive experience in the biopharmaceutical sector to drive strategic growth for the company.
- Board Expansion: Jarrett will also serve on the Board of Directors, enhancing the company's governance structure and decision-making efficiency, which is expected to positively impact the company's long-term growth trajectory.
- New Board Members: The company has appointed Cameron Turtle and Mike Landsittel to the Board, with Turtle being the CEO of Spyre Therapeutics and Landsittel a former CFO of Blueprint Medicines, bringing additional industry expertise and resources to the company.
- Chairman Change: Peter Harwin has been named Chairman of the Board, and as a founding partner at Fairmount Funds Management, his leadership is expected to enhance the company's influence in capital markets, supporting future financing and strategic planning.
See More
Damora Therapeutics Names Biotechnology Expert Jennifer Jarrett as President and CEO; Welcomes Two Industry Veterans to Board of Directors
New Leadership Appointment: Damo Therapeutics has appointed Jennifer Jarrett as President and Chief Executive Officer, enhancing its leadership team.
Board Expansion: The company has also added two industry veterans to its Board of Directors, aiming to strengthen its strategic direction.
See More
Damora Therapeutics Reports 2025 Results and Pipeline Progress
- Financial Overview: Damora Therapeutics ended 2025 with $257.6 million in cash, which increased to $535 million following a public offering in February 2026, providing essential funding for Phase 3 development, despite reporting a net loss of $209.8 million, significantly higher than the previous year's $21.4 million, primarily due to costs associated with the acquisition of the mutCALR pipeline.
- Pipeline Progress: The company's lead program, DMR-001, is on track for an IND/CTA filing in mid-2026, with two proof-of-concept readouts expected in 2027, indicating its potential in treating mutant calreticulin-driven blood disorders.
- New Therapy Development: DMR-002 and DMR-003 are respectively an undisclosed mutCALR-targeted therapy and a bispecific antibody, with IND/CTA submissions anticipated in the second half of 2026 and 2027, further enhancing Damora's competitive position in the market.
- Stock Split Impact: The company implemented a 1-for-25 reverse stock split on August 26, 2024; despite a 9.22% drop in stock price to $19.20 on Thursday, it slightly rebounded to $19.21 in pre-market trading, reflecting cautious optimism in the market regarding its future developments.
See More
Galecto Reports Disappointing FY Earnings with Significant EPS Miss
- Disappointing Earnings Report: Galecto's FY earnings report reveals a GAAP EPS of -$3.98, missing expectations by $3.02, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, Galecto reported cash and cash equivalents of approximately $257.6 million, which, while providing some liquidity, may be insufficient to support ongoing operations amid persistent losses.
- Executive Appointments: The company has appointed former Blueprint Medicines executives as COO and CMO, aiming to enhance strategic direction and operational efficiency through experienced leadership, potentially improving competitive positioning in the market.
- Market Sentiment Outlook: Given the disappointing earnings and executive changes, market sentiment towards Galecto is expected to be cautious, which may lead to stock price volatility and affect long-term investor confidence.
See More
